We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Collaborators to Develop Technologies to Turn Cell Therapy into a Clinical Tool

By LabMedica International staff writers
Posted on 04 Jun 2012
European collaborators aim to advance the development of technologies that will enable clinicians to employ cell therapy techniques as routine clinical treatments.

The Karolinska University Hospital (Stockholm, Sweden) and GE Healthcare Life Sciences (Little Chalfont, United Kingdom) recently signed an agreement to collaborate for three years in a program to explore and advance future technology and workflow needs for cell therapy in a clinical setting.

Karolinska University Hospital is already involved in pioneering cell therapy trials for the treatment of cancer as well as neurological and metabolic disorders. More...
GE Healthcare Life Sciences is a well-known developer and manufacturer of biotherapeutic products. Furthermore, the company has established a research program aimed at developing new technologies to exploit cell therapy techniques.

To turn cell therapy into a routine clinical tool will require new technologies to grow, handle, process, and analyze cells. In addition, robust, reproducible, and standardized protocols and workflows for manufacturing and quality control must be established. Karolinska University Hospital and GE Healthcare have endeavored to work together to make this happen.

Dr. Johan Permert, director for development and innovation at Karolinska University Hospital said, “Our expectation from this exciting and innovative collaboration is to solve problems that hinder cell therapies from becoming an established treatment. By involving not only researchers and industry partners but also the public healthcare system, we are aiming to develop methods and tools that accelerate the implementation of cell therapies into standard treatment. In addition, this collaboration is a first initiative to develop enhanced interaction between Karolinska University Hospital and industry, which will lead to improved care chains.”

Dr. Amr Abid, general manager cell technologies at GE Healthcare Life Sciences, said, “Cell therapy offers the hope that one day there will be treatments for diseases for which today there is no cure. Our vision at GE Healthcare is to help make that hope reality for patients and doctors by developing the technologies and workflows that will help bring cell therapy to the clinic. These are big challenges which will only be overcome by working hand-in-hand with the world’s foremost experts in clinical cell therapy, which is why we are delighted to be working with the world-class cell therapy team at Karolinska.”

Related Links:
Karolinska University Hospital
GE Healthcare Life Sciences


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.